MedTrace Logo

Modified Zhiwang Decoction Combined With Methotrexate in the Treatment of Early Rheumatoid Arthritis

NCT05508815 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-05-25

No results posted yet for this study

Summary

The aim of this study is to evaluate the effectiveness and safety of Modified Zhiwang Decoction in combination with methotrexate for the treatment of early RA patients and a parallel-group, single-center randomized controlled clinical study was designed.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Modified Zhiwang Decoction Combined with methotrexate

Modified Zhiwang Decoction 100 ml (twice, per day) and methotrexate (7.5-15mg, once a week) for 12 weeks.

DRUG

Methotrexate

Methotrexate(7.5-15mg, once a week) for 12 weeks.

Sponsors & Collaborators

  • Beijing University of Chinese Medicine

    lead OTHER

Principal Investigators

  • Yuan Xu · China-Japan Friendship Hospital

  • Cheng Xiao · China-Japan Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-09
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05508815 on ClinicalTrials.gov